Wall Street analysts expect OptimizeRx Co. (NASDAQ:OPRX) to announce earnings of $0.03 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for OptimizeRx’s earnings. The highest EPS estimate is $0.06 and the lowest is $0.01. OptimizeRx posted earnings of ($0.03) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 200%. The business is expected to announce its next earnings report on Wednesday, May 1st.
According to Zacks, analysts expect that OptimizeRx will report full year earnings of $0.38 per share for the current fiscal year, with EPS estimates ranging from $0.29 to $0.43. For the next fiscal year, analysts expect that the firm will post earnings of $0.62 per share, with EPS estimates ranging from $0.48 to $0.75. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for OptimizeRx.
Several brokerages recently commented on OPRX. Zacks Investment Research upgraded OptimizeRx from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Friday, January 4th. William Blair began coverage on OptimizeRx in a report on Thursday, January 3rd. They issued an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $18.25.
OPRX stock traded down $0.07 during trading on Monday, hitting $12.32. The company had a trading volume of 9,546 shares, compared to its average volume of 49,069. OptimizeRx has a one year low of $2.30 and a one year high of $18.39. The stock has a market capitalization of $142.72 million, a PE ratio of 246.40, a PEG ratio of 1.28 and a beta of 1.03.
In related news, major shareholder Awm Investment Company, Inc. sold 21,397 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.05, for a total value of $322,024.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of OptimizeRx during the 4th quarter worth approximately $55,000. Bank of America Corp DE boosted its holdings in shares of OptimizeRx by 15.8% during the 4th quarter. Bank of America Corp DE now owns 15,302 shares of the company’s stock worth $168,000 after buying an additional 2,084 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of OptimizeRx by 71.5% during the 4th quarter. Northern Trust Corp now owns 17,474 shares of the company’s stock worth $192,000 after buying an additional 7,283 shares in the last quarter. Alambic Investment Management L.P. bought a new position in shares of OptimizeRx during the 4th quarter worth approximately $289,000. Finally, Tibra Equities Europe Ltd bought a new position in shares of OptimizeRx during the 1st quarter worth approximately $338,000. Hedge funds and other institutional investors own 45.94% of the company’s stock.
OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.
Further Reading: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.